During 2003–2012, 8 clusters of meningococcal disease were identified in Rio de Janeiro State, Brazil, all caused by serogroup C
The last epidemic of
Public health surveillance of meningococcal disease in Rio de Janeiro State is conducted by the Meningitis Advisory Committee of the State Department of Health, which uses data obtained from 2 surveillance sources: mandatory reports of meningococcal disease cases and reports of laboratory-confirmed
A cluster was defined as ≥3 cases of meningococcal disease with a clear epidemiologic link and with
We identified 8 clusters involving 46 cases that occurred during 2003–2012; all were caused by serogroup C
Spatial distribution of 8 meningococcal disease clusters caused by 3 different clonal complexes (cc) of
The genetic lineage of
Serogroup C disease increased from 121 (26%) of 463 cases during 2000–2003, to 174 (44%) of 394 cases during 2004–2007, and to 499 (84%) of 594 cases during 2008–2012 (p<0.01). The case-fatality rate of serogroup C disease also increased during the same periods: 12%, 14%, and 19% (p = 0.03), respectively. These serogroup C isolates were mainly represented by 4 serologic phenotypes: C:23:P1.14–6 (60%), C:4,7:P1.7,1 (15%), C2a:P1.5,2 (12%), and C:4,7:P1.19,15 (6%).
New cases associated with serogroup C meningococcal disease clusters occurred within an average of 15 days (range 1–30 days), and those infected had proximity to each other (same household, vicinity, daycare center, primary school, or workplace). The average age of patients was 13 years (range 10 months–51 years). The clinical signs and symptoms recorded when the person sought medical treatment were fever (98%), vomiting (80%), hemorrhagic rash (67%), headache (65%), neck stiffness (50%), impaired consciousness (41%), diarrhea (15%), abdominal pain (15%), convulsions (13%), sore throat (9%), and myalgia (6%). The overall case-fatality rate was 28% (13/46), ranging from 17% (cc103) to 44% (cc11) (
| Serogroup/year | Genotype (no. isolates)/clonal complex | Date of emergence of cluster-related clone (date of commencement of cluster) | |
|---|---|---|---|
| C:2a | ST-11 | ||
| 1990 | 2-184:P1.5-1,2-2:F1-1:ST-5121 (1) | ||
| 1995–1997 | 2-2:P1.5,2:F3-6:ST-11 (5) | ||
| 1997 | 2-60:P1.5,2:F3-6:ST-7849 (1) | ||
| 2000 | 2-145:P1.5,2:F1-1:ST-11 (1) | ||
| 2001 | 2-184:P1.5-1,2-2:F1-1:ST-5121 (1) | ||
| 2007–2009 | 2-2:P1.5-1,10-8:F3-6:ST-11 (9) | February 2007 (February 2007, January 2008) | |
| 2009 | 2-2:P1.5-1,5-11:F3-6:ST-11 (1) | ||
| 2010 | 2-2:P1.5-1,10-8:F3-6:ST-9452 (3) | May 2010 (May 2010) | |
| C:2b | ST-8 | ||
| 1990 | 2-3:P1.18-1,3:F3-1:ST-8 (1) | No cluster associated with this clonal complex | |
| 1992 | 2-3:P1.18-1,3:F3-9:ST-8 (2) | ||
| 1995–1997 | 2-30:P1.5-2,10:F5-2:ST-8 (1) | ||
| 2-3:P1.18-1,3:F3-1:ST-8 (1) | |||
| 2-30:5-2,10:F5-2:ST-153 (8)* | |||
| 2-3:18-1,3:F3-9:ST-7769 (1) | |||
| 2-30:5-2,10:F5-2:ST-7713 (1) | |||
| 2002† | 2-30:5-2,10:F5-2:ST-153 (1) | ||
| 2-30:5-2,10:F5-2:ST-7705 (1) | |||
| C:4,7 | ST-32 | ||
| 1994 | 3-1:P1.19,15:F5-1:ST-7709 (1) | ||
| 1998–2010 | 3-79:P1.7-1,1:F5-1:ST-639 (16) | June 1998 (July 2009) | |
| 3-1:P1.19,15:F1-80:ST-33 (1) | |||
| 3-299:P1.7-1,1:F5-1:ST-639 (2) | |||
| 3-1:P1.19,15:F5-1:ST-33 (2) | |||
| 3-79:P1.19,15:F5-1:ST-639 (1) | |||
| 3-1:P1.19,15:F5-1:ST-34 (1) | |||
| 3-1:P1.19,15:F5-1:ST-639 (3) | |||
| 3-79:P1.7-1,1:F5-1:ST-7692 (1) | |||
| 3-79:P1.7-1,1:F5-1:ST-7696 (1) | October 2006 (October 2006) | ||
| 3-294:P1.7-1,1:F5-1:ST-639 (1) | |||
| 2007 | 3-300:P1.18-1,3:F5-37:ST-41 (1) | No cluster associated with this clonal complex | |
| C:4,7 | No clonal complex | ||
| 1993–1994 | 3-27:P1.20,9:F1-7:ST-7690 (3) | No cluster associated with these strains | |
| 3-1:P1.21,16:F1-20:ST-7712 (1) | |||
| 2003 | 3-1:P1.5,15:F4-3:ST-7691 (1) | ||
| C:19 | ST-41/44, ST-174, and ST-269 | ||
| 1993–1995 | 3-295:P1.5-1,10-4:F4-21:ST-3772 (1) | No cluster associated with these clonal complexes | |
| 3-295:P1.5-1,10-4:F5-1:ST-3772 (1) | |||
| 2007 | 3-35:P1.21,16:F5-13:ST-7817 (1) | ||
| 3-71:P1.19,15:F5-2:ST-437 (1) | |||
| C:23 | ST-103 | ||
| 2001–2010 | 2-23:P1.22,14-6:F1-80:ST-3779 (1) | ||
| 2-23:P1.22,14-6:F3-9:ST-3779 (13) | July 2001 (February 2012) | ||
| 2-23:P1.22,14-6:F5-92:ST-7689 (1) | |||
| 2-23:P1.22,14-6:F3-9:ST-3780 (14) | July 2003 (April 2012) | ||
| 2-23:P1.22,14-6:F1-5:ST-5727 (1) | |||
| 2-23:P1.22,14-6:F3-9:ST-7708 (1) | September 2003 (September 2003) | ||
| 2-23:P1.5,14-6:F3-9:ST-5122 (1) | |||
| 2-23:P1.22,14-6:F3-9:ST-5122 (2) | |||
| 2-23:P1.22,14-6:F5-92:ST-5338 (1) | |||
| 2-167:P1.22,14-6:F3-9:ST-3779 (3) | |||
| 2-23:P1.18-1,3:F3-9:ST-3779 (3) | |||
| 2-23:P1.22,14-6:F3-9:ST-8732 (1) | |||
| C:23 | No clonal complex | ||
| 2010 | 2-23:P1.22,14-6:F3-9:ST-8730 (1) | No cluster associated with this strain | |
*No invasive C:2b isolate has been recovered since 2002. †The clone associated with the last epidemic of serogroup C disease in 1994.
Isolates assigned to clonal complex (cc) 11, cc32, and cc103 were associated with the clusters of meningococcal disease (Technical
Clusters of meningococcal disease were a prominent feature of
Although the annual incidence rate remained stable (2–3 cases/100,000 population), clusters of meningococcal disease marked a change in the epidemiology of
Chemoprophylaxis to control clusters has been ineffective in preventing new cases, possibly because transmission might have been occurring among social networks that did not receive chemoprophylaxis. In addition, it is not known whether chemoprophylaxis reduces risk in educational institutions (
Table showing characteristics of patients from clusters of serogroup C meningococcal disease, Rio de Janeiro State, Brazil, 2003–2012
The study was presented in part in the 18th International Pathogenic Neisseria Conference, September 9–14, 2012, Würzburg, Germany.
We thank the staff of the National Meningitis Reference Center for serologictyping, the staff of the microbiology laboratories for providing meningococcal isolates, all health professionals involved in the investigation of communicable diseases, Mônica de A. F. M. Magalhães and Fabiane Bertoni for the digital map, and Julia Bennett and Keith Jolley for curation of the MLST database for
This work was supported in part by a Fogarty International Center Global Infectious Diseases Research Training Program grant, National Institutes of Health, to the University of Pittsburgh (D43TW006592).
L.H.H. receives funding from the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases. He has received research support and lecture fees from Sanofi Pasteur; lecture fees from Novartis Vaccines; and has served as a consultant to GlaxoSmithKline, Merck, Novartis Vaccines, Sanofi Pasteur, and Pfizer. Financial ties of L.H.H. with industry were terminated before he became a voting member of the Advisory Committee on Immunization Practices in July 2012.
Dr Barroso is a consultant in communicable disease control and a researcher in public health at the Oswaldo Cruz Institute, Brazil. His research interests focus on meningococcal disease and bacterial epidemiology.